Tysabri PDUFA date extended by FDA

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Tysabri PDUFA date extended by FDA

Postby MSUK » Thu Oct 20, 2011 5:06 am

Image


Biogen Idec and Elan Corporation, plc announced that the U.S. Food and Drug Administration (FDA) has extended the initial PDUFA date for its review of the supplemental Biologics License Application (sBLA) for Tysabri(R) (natalizumab).

The sBLA was submitted in December 2010 to update the Prescribing Information for Tysabri to include anti-JC virus antibody status as a factor to help stratify the risk of progressive multifocal leukoencephalopathy (PML) in the Tysabri-treated population. The 3 month extension is a standard extension period.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1905
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2225
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Return to Tysabri (Antegren or Natalizumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service